Compare Boston Scientific Corporation (BSX) vs Sirius XM Holdings Inc (SIRI) Price & Performance

Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.

BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.

Sirius XM Holdings (SIRI) trades at $28.275, down 1.75% today, with a bearish technical signal and mixed earnings history including a Q2 2026 miss. The company maintains stable cash flow, with Q2 revenue up 1% year-over-year and raised 2026 guidance. Valuation appears attractive with a P/E of 11.56 and P/B below 1, while a $0.27 dividend provides income support.

Outlook: SIRI offers value with solid fundamentals and shareholder returns, but faces competitive pressures and subscriber volatility. Risks include high debt and market sentiment shifts. Analysts see 17% upside to the $33.17 consensus target, supporting a cautious buy view for income-focused investors.